Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Methods for Controlling Microbial Growth

Methods for Controlling Microbial Growth

Microbial growth control refers to various methods employed to inhibit, reduce, or eliminate microorganisms to ensure safety and hygiene across different settings. These methods are categorized based on the target environment and the level of microbial control required.Biocides are versatile agents designed to control microorganisms by either inhibiting their growth or outright killing them. These agents work through various physical, chemical, mechanical, or biological mechanisms. The...

Antimicrobial Effectiveness

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic and environmental drivers of craniofacial, brain, and pituitary disorders.

Endocrine reviews·2026

Same author

Detection of anti-fesavirus 4 antibodies in plasma samples from cats in Japan.

The Journal of veterinary medical science·2026

Same author

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

JAMA oncology·2026

Same author

Caco-2 Cell Co-Culture Alters the Molecular Size of Igl1 and Its Extracellular Fragments in <i>Entamoeba histolytica</i>.

Pathogens (Basel, Switzerland)·2026

Same author

Application of antibody-like Down syndrome cell adhesion molecules isolated from immunized Kuruma shrimp for detection of human pathogens.

International journal of biological macromolecules·2026

Same author

Long-term imaging characteristics of the pancreas related to diabetes induced by immune checkpoint inhibitor therapy.

Acta diabetologica·2026

Search research articles

Related Experiment Video

Updated: Dec 3, 2025

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay

Published on: April 29, 2020

Nullscript inhibits Cryptosporidium and Toxoplasma growth.

Fumi Murakoshi¹, Hironori Bando², Tatsuki Sugi³

¹National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido, 080-8555, Japan; Department of Infectious Diseases, Kyoto Prefectural University of Medicine, 465, Kawaramachi-hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan; Laboratory of Sustainable Animal Environment, Graduate School of Agricultural Science, Tohoku University, Yomogida 232-3, Naruko-onsen, Osaki, Miyagi, 989-6711, Japan.

International Journal for Parasitology. Drugs and Drug Resistance

|October 29, 2020

Summary

A new compound, Nullscript, shows promise in treating parasitic infections like Cryptosporidium and Toxoplasma. It effectively inhibits parasite growth with lower toxicity, offering hope for immunocompromised patients.

Keywords:

Cryptosporidium HDAC inhibitor Nullscript Toxoplasma

More Related Videos

Studying Cryptosporidium Infection in 3D Tissue-derived Human Organoid Culture Systems by Microinjection

Studying Cryptosporidium Infection in 3D Tissue-derived Human Organoid Culture Systems by Microinjection

Published on: September 14, 2019

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

Related Experiment Videos

Last Updated: Dec 3, 2025

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay

Determination of Chemical Inhibitor Efficiency against Intracellular Toxoplasma Gondii Growth Using a Luciferase-Based Growth Assay

Published on: April 29, 2020

Studying Cryptosporidium Infection in 3D Tissue-derived Human Organoid Culture Systems by Microinjection

Studying Cryptosporidium Infection in 3D Tissue-derived Human Organoid Culture Systems by Microinjection

Published on: September 14, 2019

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

Area of Science:

Parasitology
Drug Discovery
Immunology

Background:

Cryptosporidium and Toxoplasma infections pose significant global health challenges, particularly for immunocompromised individuals.
Current treatments like nitazoxanide have limited efficacy and poor patient tolerance.
There is an urgent need for novel therapeutic agents against these opportunistic parasitic infections.

Purpose of the Study:

To screen epigenetic compounds for inhibitory activity against Cryptosporidium parvum and Toxoplasma gondii.
To identify novel drug candidates with improved efficacy and safety profiles.
To evaluate the therapeutic potential of identified compounds in preclinical models.

Main Methods:

Screening of epigenetic compound libraries against C. parvum growth.
In vitro assessment of compound efficacy and host cell toxicity.
In vivo evaluation of lead compounds in a Cryptosporidium-infected SCID mouse model.

Main Results:

Nullscript was identified as a potent inhibitor of both C. parvum and T. gondii growth.
Nullscript demonstrated reduced toxicity to host cells compared to existing treatments.
Administration of Nullscript significantly reduced oocyst excretion in C. parvum-infected mice.

Conclusions:

Nullscript represents a promising novel therapeutic candidate for cryptosporidiosis and toxoplasmosis.
The compound's dual activity against both parasites warrants further investigation.
Nullscript's favorable safety and efficacy profile suggests potential clinical utility, especially in immunocompromised populations.